Lusaris Therapeutics, Inc.

Founded in 2021 and based in Massachusetts, US, Lusaris Therapeutics, Inc. is a biotechnology company focused on developing next-generation serotonergic neuroplastogen medicines for the treatment of severe neuropsychiatric and neurological illnesses. As of 2022, Andrew Levin is the interim CEO of the company. In November 2022, Lusaris Therapeutics, Inc.

raised USD 60 million in Series A funding from RA Capital Management, including Boxer Capital, Deep Track Capital, and Venrock Healthcare Capital Partners. The company provides its lead product, LSR-1019, which is a sublingual formulation of 5-MeO-DMT, an acting and clearing serotonergic psychedelic in development for treatment-resistant depression and other neuropsychiatric conditions. The firm's products also include LSR-2000, which is a late-stage discovery program evaluating serotonergic neuroplastogens for the prevention of migraines and cluster headaches, and LSR-3000, which is a discovery program focused on developing therapies suitable for chronic dosing by maintaining broad serotonergic receptor activation. The organization plans to use the November 2022 funding to start medical trials and further develop its product, LSR-1019.